NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Friday, said the U.S. Food and Drug Administration or FDA approved over-the-counter Nexium® 24HR taking a key step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years.
The company stated that in 2012 it acquired exclusive global rights from AstraZeneca to market non-prescription Nexium®.
The addition of Nexium® 24HR to the Pfizer Consumer Healthcare portfolio expands the breadth of categories in which we help consumers better manage their health, and extends the value of the world's leading prescription acid blocker brand, the company noted.
Pfizer said it continues to work closely with AstraZeneca and retail partners to make Nexium® 24HR available to consumers in the U.S., with other markets in Europe expected to follow this year.
Copyright RTT News/dpa-AFX
© 2014 AFX News
